AstraZeneca PLC American Depositary Shares (AZN)
NASDAQ (NGS) NASDAQ (NGS) Primary 
EU Clears AZN's Etcamah Combo for First-Line ER-Positive Breast Cancer
AstraZeneca secures EU approval for Etcamah in combination with a CDK4/6 inhibitor for first-line treatment of advanced ER-positive breast cancer patients.
AstraZeneca Wins EU Approval for Breast-Cancer Drug as U.S. Review Continues
The approval opens a big market for camizestrant as U.S. regulators continue to review the company's application there.
Jefferies says September lung data can offset AstraZeneca trial failure
Jefferies believes detailed data on AstraZeneca PLC's (LSE:AZN, NASDAQ:AZN) experimental lung drug tozorakimab could more than compensate investors for the recent failure of a separate heart trial. The bank has reiterated its buy rating and 17,500p price target, implying 41% upside from the current 12,380p, and flagged the 8 September presentation at the European Respiratory Society congress as the key catalyst.
Stay Ahead of the Game With Astrazeneca (AZN) Q2 Earnings: Wall Street's Insights on Key Metrics
Evaluate the expected performance of Astrazeneca (AZN) for the quarter ended June 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Biotech's takeover boom may be running out of buyers
Biotech dealmaking has reached a level this year that has already outstripped the whole of 2025, and RBC Capital Markets thinks the pace is unlikely to hold. Cumulative deal value in the first half of 2026 came to $78 billion, against $42 billion for the entirety of last year, according to the bank's half-year sector review.
Astrazeneca (AZN) Falls More Steeply Than Broader Market: What Investors Need to Know
Astrazeneca (AZN) closed the most recent trading day at $164.52, moving 2.59% from the previous trading session.
AZN Inks Deal With Dizal to In-License Rights to Lung Cancer Drug
AstraZeneca is licensing Zegfrovy from Dizal in a deal worth up to $1.5B, expanding its lung cancer portfolio with a marketed EGFR therapy.
AstraZeneca's Oncology Engine Keeps Running Despite Wainua Setback
On July 27, AstraZeneca PLC will report its results for the second quarter of 2026. As a reminder, its revenue rose 12.5% year-over-year to $15.29 billion in Q1. Enhertu, one of the key growth drivers of AstraZeneca's oncology franchise, generated $831 million in revenue in Q1, up 39.4% YoY and 4.1% QoQ.
AstraZeneca to pay up to $1.5bn for global rights to lung cancer pill
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) has agreed to pay $600 million upfront to secure worldwide rights to a lung cancer pill developed by China's Dizal Pharmaceutical. The Cambridge-based drugmaker could pay a further $900 million if the treatment hits certain development, regulatory and sales targets.
AstraZeneca Enters Exclusive License Deal For Lung Cancer Drug Zegfrovy For Up to $1.5 Billion
AstraZeneca entered into an exclusive global license agreement with China's Dizal Pharmaceutical for the lung cancer treatment.
AstraZeneca to license lung cancer drug from China's Dizal Pharmaceutical
AstraZeneca will pay Dizal Pharmaceutical $600 million upfront for global rights to one of its drugs for a type of lung cancer, the Chinese drugmaker said in a filing to the Shanghai stock exchange Tuesday.
AstraZeneca Updates 2030 Sustainability Goals as AI and Emissions Cuts Take Center Stage
Astrazeneca NYSE: AZN told investors and analysts that it is continuing to embed sustainability into its business strategy while updating some of its 2030 targets to reflect growth and lessons learned from existing programs.
